According to their latest 13F filings, institutional investors made a series of notable moves in Thermo Fisher Scientific (TMO), highlighting conviction in the company’s role as a global leader in life sciences tools, diagnostics, and biopharma services. The stock continues to attract attention from some of the world’s most prominent asset managers, with multiple funds significantly increasing their positions.Let’s examine some of the most notable changes:Grantham, Mayo, Van Otterloo & Co. LLC (Jeremy Grant ...